Economic Analysis of the Urinary Incontinence Treatment Network Trials (E-UITN)

描述（由申请人提供）：尿失禁（UI）是女性的常见问题，导致痛苦和限制日常活动。UI的成本是巨大的，在美国每年占300亿美元，超过所有乳腺癌和妇科癌症的总和。Increased显著降低生活质量，并与类似于阿尔茨海默病和中风的严重受损的健康状况评级相关。 为了评估女性尿失禁常用治疗的长期结果，NIDDK正在赞助尿失禁治疗网络（UNAN）。该机构正在进行两项随机临床试验，比较压力性UI的手术治愈率，另一项试验评估药物与药物加行为疗法对冲动性UI的疗效。 虽然失禁的干预是昂贵的，但它们有可能改善UI，降低相关成本并提高生活质量。然而，干预措施的健康益处值得付出代价吗？这项研究的目的是对每一项试验中两种干预措施的成本和健康效益进行比较。具体目标是：1）描述UI治疗对UI成本和健康相关生活质量的影响; 2）评估治疗后UI成本和健康相关生活质量变化的预测因素; 3）估计成本效益（每次治疗成功的增量成本，由每次试验定义）; 4）估计替代干预措施的成本（即，每质量调整生命年（QALY）的增量成本）。主要成本效用分析将是从社会角度进行的试验内意向治疗分析，时间范围为2年。其他成本分析将使用终生时间范围，并包括疾病建模，以评估终生成本和获益。UI的高经济和生活质量成本以及每项研究中治疗效果差异的可能性使其成为成本效用分析的重要领域。由于公用事业涵盖了所有潜在的健康相关效益，成本效用分析是一种理想的方法来检验假设，即更昂贵的干预措施将具有与目前接受的医疗干预措施相当的每质量调整生命年增量成本。 该E-CFDN提供了一个有效的机会，调查的成本和成本效用的治疗UI。该研究汇集了一组在经济学，成本效益和UI治疗方面具有专业知识的高级研究人员。E-CORN将为失禁的常用治疗提供关键的经济数据。

DESCRIPTION (provided by applicant): Urinary incontinence (UI) is a common problem among women, causing distress and limiting daily activities. The costs of UI are substantial, accounting for $30 billion per year in the U.S., more than for all breast and gynecological cancers combined. Incontinence substantially decreases quality of life and is associated with severely impaired rating of health status similar to Alzheimer's disease and stroke. To evaluate the long-term outcomes of commonly used treatments for female UI, the NIDDK is sponsoring the Urinary Incontience Treatment Network (UITN). The UITN is conducting two randomized clinical trials comparing cure rates of surgeries for stress UI and one trial evaluating the efficacy of drug vs. drug plus behavioral therapy for urge UI. Although interventions for incontinence are costly, they have the potential to improve UI, decrease associated costs and improve quality of life. Yet, are the health benefits of the interventions worth the costs? The goal of this study, the Economic Analyses of the UITN (E-UITN), is to compare the costs and health benefits of the two interventions in each UITN trial. The specific aims are to 1) describe the effect of UI treatment on UI costs and health-related quality of life; 2) assess predictors of changes in UI costs and health-related quality of life following treatment; 3) estimate the cost-effectiveness (incremental cost per treatment success, defined by each trial); and 4) estimate the costutility of the alternative interventions (i.e., incremental cost per quality-adjusted life year (QALY)). The primary cost-utility analyses will be within-trial, intention-to-treat analyses conducted from the societal perspective with a two-year time horizon. Additional costutility analyses will use the lifetime time horizon and include disease modeling to assess lifetime costs and benefits. The high economic and quality of life costs of UI and the probability of differential efficacy of the treatments within each study make this an important area to explore with cost-utility analysis. Since utilities capture all potential health-related benefits, cost-utility analysis is an ideal method to test the hypothesis that a more expensive intervention will have an incremental cost per QALY that is comparable with currently accepted medical interventions. The E-UITN offers an efficient opportunity to investigate the costs and cost-utility of treatments for UI. The study assembles a group of senior investigators with expertise in economics, cost-effectiveness and UI treatment. The E- UITN will provide critical economic data for commonly used treatments for incontinence.